tbuckley/cabot-search huggingface dataset:
Population size, HIV prevalence, and antiretroviral therapy coverage among key populations in sub-Saharan Africa: collation and synthesis of survey data, 2010–23
Authors: Oliver Stevens, Keith Sabin, Rebecca L Anderson, Sonia Arias Garcia, Kalai Willis, Amrita Rao, Anne F McIntyre, Elizabeth Fearon, Emilie Grard, Alice Stuart-Brown, Frances Cowan, Louisa Degenhardt, James Stannah, Jinkou Zhao, Avi J Hakim, Katherine Rucinski, Isabel Sathane, Makini Boothe, Lydia Atuhaire, Peter S Nyasulu, Mathieu Maheu-Giroux, Lucy Platt, Brian Rice, Wolfgang Hladik, Stefan Baral, Mary Mahy, Jeffrey W Imai-Eaton
Journal: The Lancet Global Health (2024)

Key population HIV programmes in sub-Saharan Africa require epidemiological information to ensure equitable and universal access to effective services. We aimed to consolidate and harmonise survey data among female sex workers, men who have sex with men, people who inject drugs, and transgender people to estimate key population size, HIV prevalence, and antiretroviral therapy (ART) coverage for countries in mainland sub-Saharan Africa.
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
Authors: Stefan Zielen, Thomas Crawford, Luca Benatti, Mauro Magnani, Matthias Kieslich, Monique Ryan, Isabelle Meyts, Sheffali Gulati, Rupam Borgohain, Ravi Yadav, Pramod Pal, Anaita Hegde, Suresh Kumar, Anand Venkateswar, Vrajesh Udani, Kollencheri P Vinayan, Andreea Nissenkorn, Elisa Fazzi, Vincenzo Leuzzi, Asbjørg Stray-Pedersen, Barbara Pietrucha, Samuel I Pascual, Riadh Gouider, Mary Kay Koenig, Steve Wu, Susan Perlman, Dirk Thye, Guenter Janhofer, Biljana Horn, William Whitehouse, Howard Lederman
Journal: The Lancet Neurology (2024)
The costs and benefits of scaling up interventions to prevent poor birth outcomes in low-income and middle-income countries: a modelling study
Authors: Neff Walker, Austin Heuer, Rachel Sanders, Hannah Tong
Journal: The Lancet Global Health (2024)

We estimated the benefits and costs of a set of preventive interventions that could be delivered during antenatal care to prevent poor birth outcomes, including small-for-gestational-age and preterm births. We built on the assumptions and analyses underlying the Lancet Series on small vulnerable newborns (SVNs) and extended that work by incorporating more recent data, focusing only on the subset of preventive interventions, and examining a broader range of effects. A primary aim of the study was to provide a framework that decision makers could use to design programmes for women and children.
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Authors: Halimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, Djibrilla Issiaka, Aye Diallo, Seydou Traore, Ibrahim H Soumbounou, Santara Gaoussou, Irfan Zaidi, Almahamoudou Mahamar, Oumar Attaher, Michal Fried, Blair J Wylie, Rathy Mohan, Viyada Doan, Justin Y A Doritchamou, Amagana Dolo, Robert D Morrison, Jing Wang, Zonghui Hu, Kelly M Rausch, Amatigue Zeguime, Tooba Murshedkar, Natasha Kc, B Kim Lee Sim, Peter F Billingsley, Thomas L Richie, Stephen L Hoffman, Alassane Dicko, Patrick E Duffy
Journal: The Lancet Infectious Diseases (2024)
Effectiveness and impact of monovalent rotavirus vaccination in Afghanistan: a test-negative case–control analysis
Authors: Palwasha Anwari, Eleanor Burnett, Najibullah Safi, Akmal Samsor, Helah Safi, Tyler P Chavers, Umesh D Parashar, Andrew D Clark, Jacqueline E Tate
Journal: The Lancet Global Health (2024)

Afghanistan introduced monovalent rotavirus vaccine (Rotarix) into its national immunisation schedule in January, 2018. While post-licensure studies have shown substantial declines in rotavirus gastroenteritis cases and deaths globally, there is little evidence of rotavirus vaccine effectiveness and impact from low-income countries in Asia. We aimed to evaluate the effectiveness of the Rotarix vaccine and the impact of Rotarix vaccine on rotavirus gastroenteritis hospitalisations (ie, hospital admissions) among children younger than 5 years in Afghanistan.
Multimodal representations of biomedical knowledge from limited training whole slide images and reports using deep learning
Authors: Niccolò Marini, Stefano Marchesin, Marek Wodzinski, Alessandro Caputo, Damian Podareanu, Bryan Cardenas Guevara, Svetla Boytcheva, Simona Vatrano, Filippo Fraggetta, Francesco Ciompi, Gianmaria Silvello, Henning Müller, Manfredo Atzori
Journal: Medical Image Analysis (2024)

The increasing availability of biomedical data creates valuable resources for developing new deep learning algorithms to support experts, especially in domains where collecting large volumes of annotated data is not trivial. Biomedical data include several modalities containing complementary information, such as medical images and reports: images are often large and encode low-level information, while reports include a summarized high-level description of the findings identified within data and often only concerning a small part of the image. However, only a few methods allow to effectively link the visual content of images with the textual content of reports, preventing medical specialists from properly benefitting from the recent opportunities offered by deep learning models. This paper introduces a multimodal architecture creating a robust biomedical data representation encoding fine-grained text representations within image embeddings. The architecture aims to tackle data scarcity (combining supervised and self-supervised learning) and to create multimodal biomedical ontologies. The architecture is trained on over 6,000 colon whole slide Images (WSI), paired with the corresponding report, collected from two digital pathology workflows. The evaluation of the multimodal architecture involves three tasks: WSI classification (on data from pathology workflow and from public repositories), multimodal data retrieval, and linking between textual and visual concepts. Noticeably, the latter two tasks are available by architectural design without further training, showing that the multimodal architecture that can be adopted as a backbone to solve peculiar tasks. The multimodal data representation outperforms the unimodal one on the classification of colon WSIs and allows to halve the data needed to reach accurate performance, reducing the computational power required and thus the carbon footprint. The combination of images and reports exploiting self-supervised algorithms allows to mine databases without needing new annotations provided by experts, extracting new information. In particular, the multimodal visual ontology, linking semantic concepts to images, may pave the way to advancements in medicine and biomedical analysis domains, not limited to histopathology.
The role of the microbiota–gut–brain axis in methamphetamine-induced neurotoxicity: Disruption of microbial composition and short-chain fatty acid metabolism
Authors: Lijian Chen, Kaikai Zhang, Jiali Liu, Xiuwen Li, Yi Liu, Hongsheng Ma, Jianzheng Yang, Jiahao Li, Long Chen, Clare Hsu, Jiahao Zeng, Xiaoli Xie, Qi Wang
Journal: Acta Pharmaceutica Sinica B (2024)

Methamphetamine (METH) abuse is associated with significant neurotoxicity, high addiction potential, and behavioral abnormalities. Recent studies have identified a connection between the gut microbiota and METH-induced neurotoxicity and behavioral disorders. However, the underlying causal mechanisms linking the gut microbiota to METH pathophysiology remain largely unexplored. In this study, we employed fecal microbiota transplantation (FMT) and antibiotic (Abx) intervention to manipulate the gut microbiota in mice administered METH. Furthermore, we supplemented METH-treated mice with short-chain fatty acids (SCFAs) and pioglitazone (Pio) to determine the protective effects on gut microbiota metabolism. Finally, we assessed the underlying mechanisms of the gut-brain neural circuit in vagotomized mice. Our data provide compelling evidence that modulation of the gut microbiome through FMT or microbiome knockdown by Abx plays a crucial role in METH-induced neurotoxicity, behavioral disorders, gut microbiota disturbances, and intestinal barrier impairment. Furthermore, our findings highlight a novel prevention strategy for mitigating the risks to both the nervous and intestinal systems caused by METH, which involves supplementation with SCFAs or Pio.
M2BPGi Correlated with Immunological Biomarkers and Further Stratified Recurrence Risk in Patients with Hepatocellular Carcinoma
Authors: I-Cheng Lee, Hao-Jan Lei, Lei-Chi Wang, Yi-Chen Yeh, Gar-Yang Chau, Cheng-Yuan Hsia, Shu-Cheng Chou, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang
Journal: Liver Cancer (2024)

Introduction: Novel biomarkers reflecting liver fibrosis and the immune microenvironment may correlate with the risk of hepatocellular carcinoma (HCC) recurrence. This study aimed to evaluate the prognostic value of serum biomarkers in predicting HCC recurrence. Methods: Serum biomarkers, including M2BPGi, IL-6, IL-10, CCL5, VEGF-A, soluble PD-1, PD-L1, TIM-3, and LAG-3, were measured in 247 patients with HCC undergoing surgical resection. Factors associated with recurrence-free survival (RFS) and overall survival (OS) were evaluated. The ERASL-post model and IMbrave050 criteria were used to define HCC recurrence risk groups. Results: Serum M2BPGi levels significantly correlated with FIB-4 score, aspartate transaminase-to-platelet ratio index, ALBI score, alpha-fetoprotein (AFP), alanine transaminase, aspartate transaminase, IL-10, CCL5, VEGF-A, soluble PD-1, PD-L1, TIM-3, and LAG-3 levels. M2BPGi, VEGF-A, soluble PD-1, and TIM-3 levels significantly correlated with RFS. In multivariate analysis, M2BPGi &amp;gt;1.5 COI (hazard ratio [HR] = 2.100, p &amp;lt; 0.001), tumor size &amp;gt;5 cm (HR = 1.859, p = 0.002), multiple tumors (HR = 2.562, p &amp;lt; 0.001), AFP &amp;gt;20 ng/mL (HR = 2.141, p &amp;lt; 0.001), and microvascular invasion (HR = 1.954, p = 0.004) were independent predictors of RFS. M2BPGi levels significantly stratified the recurrence risk in ERASL-post and IMbrave050 risk groups. An M2BPGi-based model could significantly discriminate RFS in the overall cohort as well as in the IMbrave050 low- and high-risk groups. M2BPGi &amp;gt;1.5 COI was also an independent predictor of OS after resection (HR = 2.707, p &amp;lt; 0.001). Conclusion: Serum M2BPGi levels significantly correlated with surrogate markers of liver fibrosis, liver function, and immunology. M2BPGi is a significant predictor of HCC recurrence and survival after resection and could be incorporated into recurrence-prediction models.
Cognitive Motor Dissociation in Disorders of Consciousness
Authors: Yelena G Bodien, Judith Allanson, Paolo Cardone, Arthur Bonhomme, Jerina Carmona, Camille Chatelle, Srivas Chennu, Mary Conte, Stanislas Dehaene, Paola Finoia, Gregory Heinonen, Jennifer E Hersh, Evelyn Kamau, Phoebe K Lawrence, Victoria C Lupson, Anogue Meydan, Benjamin Rohaut, William R Sanders, Jacobo D Sitt, Andrea Soddu, Mélanie Valente, Angela Velazquez, Henning U Voss, Athina Vrosgou, Jan Claassen, Brian L Edlow, Joseph J Fins, Olivia Gosseries, Steven Laureys, David Menon, Lionel Naccache, Adrian M Owen, John Pickard, Emmanuel A Stamatakis, Aurore Thibaut, Jonathan D Victor, Joseph T Giacino, Emilia Bagiella, Nicholas D Schiff
Journal: New England Journal of Medicine (2024)

Patients with brain injury who are unresponsive to commands may perform cognitive tasks that are detected on functional magnetic resonance imaging (fMRI) and electroencephalography (EEG). This phenomenon, known as cognitive motor dissociation, has not been systematically studied in a large cohort of persons with disorders of consciousness.
An Accurate and Rapidly Calibrating Speech Neuroprosthesis
Authors: Nicholas S Card, Maitreyee Wairagkar, Carrina Iacobacci, Xianda Hou, Tyler Singer-Clark, Francis R Willett, Erin M Kunz, Chaofei Fan, Maryam Vahdati Nia, Darrel R Deo, Aparna Srinivasan, Eun Young Choi, Matthew F Glasser, Leigh R Hochberg, Jaimie M Henderson, Kiarash Shahlaie, Sergey D Stavisky, David M Brandman
Journal: New England Journal of Medicine (2024)

BackgroundBrain–computer interfaces can enable communication for people with paralysis by transforming cortical activity associated with attempted speech into text on a computer screen. Communication with brain–computer interfaces has been restricted by extensive training requirements and limited accuracy.MethodsA 45-year-old man with amyotrophic lateral sclerosis (ALS) with tetraparesis and severe dysarthria underwent surgical implantation of four microelectrode arrays into his left ventral precentral gyrus 5 years after the onset of the illness; these arrays recorded neural activity from 256 intracortical electrodes. We report the results of decoding his cortical neural activity as he attempted to speak in both prompted and unstructured conversational contexts. Decoded words were displayed on a screen and then vocalized with the use of text-to-speech software designed to sound like his pre-ALS voice.ResultsOn the first day of use (25 days after surgery), the neuroprosthesis achieved 99.6% accuracy with a 50-word vocabulary. Calibration of the neuroprosthesis required 30 minutes of cortical recordings while the participant attempted to speak, followed by subsequent processing. On the second day, after 1.4 additional hours of system training, the neuroprosthesis achieved 90.2% accuracy using a 125,000-word vocabulary. With further training data, the neuroprosthesis sustained 97.5% accuracy over a period of 8.4 months after surgical implantation, and the participant used it to communicate in self-paced conversations at a rate of approximately 32 words per minute for more than 248 cumulative hours.ConclusionsIn a person with ALS and severe dysarthria, an intracortical speech neuroprosthesis reached a level of performance suitable to restore conversational communication after brief training. (Funded by the Office of the Assistant Secretary of Defense for Health Affairs and others; BrainGate2 ClinicalTrials.gov number, NCT00912041.)
AL Amyloidosis
Authors: Miguel Mansilla Polo, Margarita Llavador-Ros
Journal: New England Journal of Medicine (2024)

A 58-year-old man presented with a 2-year history of eyelid lesions and several months of weight loss and fatigue. Scattered periorbital petechiae and purpura were noted, as well as coalescing, waxy papules on the eyelids.
Osimertinib in Stage III <i>EGFR</i> -Mutated NSCLC — Game, Set, Match
Authors: Natasha B Leighl
Journal: New England Journal of Medicine (2024)

Exactly 20 years ago, the precision-medicine revolution in lung cancer began with the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain,1,2 predicting dramatic patient benefit from EGFR tyrosine kinase inhibitors (TKIs). By 2024, routine testing for genomic alterations has expanded to nine genes with matched targeted therapies for advanced non–small-cell lung cancer (NSCLC) — EGFR, ALK, ROS1, RET, MET, KRAS, NTRK, BRAF, and ERBB2. More than half of patients with NSCLC have genomic alterations in tumor cells, including EGFR mutations in approximately 40% of patients in East Asia and 15 to 25% of those . . .
Longevity of a Brain–Computer Interface for Amyotrophic Lateral Sclerosis
Authors: Mariska J Vansteensel, Sacha Leinders, Mariana P Branco, Nathan E Crone, Timothy Denison, Zachary V Freudenburg, Simon H Geukes, Peter H Gosselaar, Mathijs Raemaekers, Anouck Schippers, Malinda Verberne, Erik J Aarnoutse, Nick F Ramsey
Journal: New England Journal of Medicine (2024)

The durability of communication with the use of brain-computer interfaces in persons with progressive neurodegenerative disease has not been extensively examined. We report on 7 years of independent at-home use of an implanted brain-computer interface for communication by a person with advanced amyotrophic lateral sclerosis (ALS), the inception of which was reported in 2016. The frequency of at-home use increased over time to compensate for gradual loss of control of an eye-gaze-tracking device, followed by a progressive decrease in use starting 6 years after implantation. At-home use ended when control of the brain-computer interface became unreliable. No signs of technical malfunction were found. Instead, the amplitude of neural signals declined, and computed tomographic imaging revealed progressive atrophy, which suggested that ALS-related neurodegeneration ultimately rendered the brain-computer interface ineffective after years of successful use, although alternative explanations are plausible. (Funded by the National Institute on Deafness and Other Communication Disorders and others; ClinicalTrials.gov number, NCT02224469.).
Case 25-2024: A 12-Year-Old Boy with Autism and Decreased Vision
Authors: Eric D Gaier, Camilo Jaimes, Ryan A Gise, Amy E Armstrong-Javors, Sarah M Kadzielski
Journal: New England Journal of Medicine (2024)

A 12-year-old boy with autism complicated by developmental delay, selective eating, and toe walking was admitted to the hospital because of decreased vision in both eyes. A diagnosis was made.
T-Cell Neoplasms after B-Cell Neoplasms — The Pre–CAR T-Cell Era
Authors: Graça M Dores, Lindsay M Morton
Journal: New England Journal of Medicine (2024)

T-cell neoplasms after treatment for B-cell neoplasms are not unique to CAR T-cell therapy. In the pre–CAR T-cell era, the risk of a T-cell neoplasm after treatment for a B-cell neoplasm was 4.8 times the risk in the general population.
Response to PARP Inhibition in <i>BARD1</i> -Mutated Refractory Neuroblastoma
Authors: Margaret Cupit-Link, Kohei Hagiwara, Matthew Nagy, Selene C Koo, Brent A Orr, Eytan Ruppin, John Easton, Jinghui Zhang, Sara M Federico
Journal: New England Journal of Medicine (2024)

Some neuroblastomas carry disabling mutations in BARD1, a homologous recombination repair gene. A child with refractory neuroblastoma and a BARD1 mutation had a sustained response after treatment with the PARP inhibitor talazoparib.
Global burden of metabolic diseases, 1990–2021
Authors: Huai Zhang, Xiao-Dong Zhou, Michael D Shapiro, Gregory Y H Lip, Herbert Tilg, Luca Valenti, Virend K Somers, Christopher D Byrne, Giovanni Targher, Wah Yang, Octavio Viveiros, Christopher Kenneth Opio, Christos S Mantzoros, John D Ryan, Kenneth Yuh Yen Kok, Nozim Adxamovich Jumaev, Nilanka Perera, Andrew Gerard Robertson, Adam Abu-Abeid, Anoop Misra, Yu Jun Wong, Elena Ruiz-Úcar, Oral Ospanov, Mehmet Celal Kızılkaya, Fei Luo, Nahum Méndez-Sánchez, Mauricio Zuluaga, Amedeo Lonardo, Hazem Al Momani, Carlos Jesus Toro-Huamanchumo, Leon Adams, Said A Al-Busafi, Ala I Sharara, Wah-Kheong Chan, Syed Imran Abbas, Silvia Sookoian, Sombat Treeprasertsuk, Ponsiano Ocama, Khalid Alswat, Alice Pik-Shan Kong, Karim Ataya, Michelle Ching Lim-Loo, Rodolfo J Oviedo, Olivia Szepietowski, Yasser Fouad, Huijie Zhang, Tamer N Abdelbaki, Christos S Katsouras, Arun Prasad, Omar Thaher, Arshad Ali, Gabriel Alejandro Molina, Ki-Chul Sung, Qin-Fen Chen, Cosmas Rinaldi Adithya Lesmana, Ming-Hua Zheng
Journal: Metabolism (2024)
Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation
Authors: Dimitrios Farmakis, Beth Davison, Katerina Fountoulaki, Sotiria Liori, Ovidiu Chioncel, Marco Metra, Jelena Celutkiene, Alain Cohen-Solal, Albertino Damasceno, Rafael Diaz, Christopher Edwards, Etienne Gayat, Maria Novosadova, Vasiliki Bistola, Peter S Pang, Piotr Ponikowski, Hadiza Saidu, Karen Sliwa, Koji Takagi, Adriaan A Voors, Alexandre Mebazaa, Gad Cotter, Gerasimos Filippatos
Journal: JACC Heart Failure (2024)
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure
Authors: Jason L Guichard, Eric L Bonno, Michael E Nassif, Taiyeb M Khumri, David Miranda, Orvar Jonsson, Hirak Shah, Tamas Alexy, Gregory P Macaluso, James Sur, Gavin Hickey, Patrick McCann, Jennifer A Cowger, Amit Badiye, Wayne D Old, Yasmin Raza, Luke Masha, Chandra R Kunavarapu, Mosi Bennett, Faisal Sharif, Michael Kiernan, Wilfried Mullens, Sandra V Chaparro, Claudius Mahr, Rohit R Amin, Lynne Warner Stevenson, Nicholas J Hiivala, Max M Owens, Andrea Sauerland, Omid Forouzan, Liviu Klein
Journal: JACC Heart Failure (2024)

Monitoring supine pulmonary artery pressures to guide heart failure (HF) management has reduced HF hospitalizations in select patients. The purpose of this study was to evaluate the effect of managing seated mean pulmonary artery pressure (mPAP) with the Cordella Pulmonary Artery sensor on outcomes in patients with HF. Following GUIDE-HF (Hemodynamic-GUIDEd Management of Heart Failure Trial), with U.S. Food and Drug Administration input, PROACTIVE-HF (A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients trial) was changed from a randomized to a single-arm, open label trial, conducted at 75 centers in the USA and Europe. Eligible patients had chronic HF with NYHA functional class III symptoms, irrespective of the ejection fraction, and recent HF hospitalization and/or elevated natriuretic peptides. The primary effectiveness endpoint at 6 months required the HF hospitalization or all-cause mortality rate to be lower than a performance goal of 0.43 events/patient, established from previous hemodynamic monitoring trials. Primary safety endpoints at 6 months were freedom from device- or system-related complications or pressure sensor failure. Between February 7, 2020, and March 31, 2023, 456 patients were successfully implanted in modified intent-to-treat cohort. The 6-month event rate was 0.15 (95% CI: 0.12-0.20) which was significantly lower than performance goal (0.15 vs 0.43; P < 0.0001). Freedom from device- or system-related complications was 99.2% and freedom from sensor failure was 99.8% through 6 months. Remote management of seated mPAP is safe and results in a low rate of HF hospitalizations and mortality. These results support the use of seated mPAP monitoring and extend the growing body of evidence that pulmonary artery pressure–guided management improves outcomes in heart failure. (Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients trial [PROACTIVE-HF]; NCT04089059)
CFTR and colorectal cancer susceptibility: an urgent need for further studies
Authors: S. Spelier, S. Derksen, R. Hofland, J.M. Beekman, B. Yetkin-Arik
Journal: Trends in cancer (2024)

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in cystic fibrosis, a multiorgan disease characterized by aberrant epithelial cell fluid secretion. Recent studies describe a connection between CFTR malfunctioning and a heightened susceptibility to colorectal cancer (CRC). Here, we outline these links and suggest directions for further studies.
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells
Authors: Yi Zhang, Miso Park, Lucy Y Ghoda, Dandan Zhao, Melissa Valerio, Ebtesam Nafie, Asaul Gonzalez, Kevin Ly, Bea Parcutela, Hyeran Choi, Xubo Gong, Fang Chen, Kaito Harada, Zhenhua Chen, Le Xuan Truong Nguyen, Flavia Pichiorri, Jianjun Chen, Joo Song, Stephen J Forman, Idoroenyi Amanam, Bin Zhang, Jie Jin, John C Williams, Guido Marcucci
Journal: Journal of Hematology & Oncology (2024)

The interleukin-1 receptor accessory protein (IL1RAP) is highly expressed on acute myeloid leukemia (AML) bulk blasts and leukemic stem cells (LSCs), but not on normal hematopoietic stem cells (HSCs), providing an opportunity to target and eliminate the disease, while sparing normal hematopoiesis. Herein, we report the activity of BIF002, a novel anti-IL1RAP/CD3 T cell engager (TCE) in AML.